scholarly journals Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma

2021 ◽  
Vol 147 ◽  
pp. 1-12
Author(s):  
Paul M.J. Clement ◽  
Linda Dirven ◽  
Marica Eoli ◽  
Juan M. Sepulveda-Sanchez ◽  
Annemiek M.E. Walenkamp ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Phase Ii ◽  
Recurrent Glioblastoma ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Neurological Functioning

scholarly journals NTOX-11. DISEASE OUTCOMES, TOXICITY PROFILES, AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RECURRENT GLIOBLASTOMA RECEIVING INTRA-ARTERIAL CARBOPLATIN SALVAGE THERAPY

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi167-vi167
Author(s):  
Anna Babcock ◽  
Meghan Hultman ◽  
Patricia Bruns ◽  
Katheryn Gilliland ◽  
Amy Schrecengost ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Salvage Therapy ◽  
Recurrent Glioblastoma ◽  
Health Related Quality ◽  
Disease Outcomes ◽  
Related Quality ◽  
Health Related

Effects of oral tazarotene on health-related quality of life in patients with severe nodulocystic acne: results from a phase ii dose-ranging study

2004 ◽  
Vol 50 (3) ◽  
pp. P18
Author(s):  
Jonathan W Kowalski ◽  
James J Leyden ◽  
Jerry Tan ◽  
Walker Patricia
Keyword(s):  
Quality Of Life ◽  
Phase Ii ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Dose Ranging

scholarly journals Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial

HemaSphere ◽  
2021 ◽  
Vol 5 (5) ◽  
pp. e562
Author(s):  
Claire N. Harrison ◽  
Nicolaas Schaap ◽  
Alessandro M. Vannucchi ◽  
Jean-Jacques Kiladjian ◽  
Eric Jourdan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Phase Ii ◽  
Patient Reported Outcomes ◽  
Health Related Quality ◽  
Patient Reported ◽  
Related Quality ◽  
Health Related ◽  
Previously Treated

scholarly journals QLIF-12. HEALTH-RELATED QUALITY OF LIFE RESULTS FROM THE RANDOMIZED PHASE II TAVAREC TRIAL ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB IN 1p/19q INTACT FIRS RECURRENCE WHO GRADE II AND III GLIOMA (EORTC 26091)

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi203-vi203
Author(s):  
Jaap C Reijneveld ◽  
Corneel Coens ◽  
Martin J B Taphoorn ◽  
Peter Sillevis Smitt ◽  
Paul M Clement ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Phase Ii ◽  
Health Related Quality ◽  
Who Grade ◽  
Randomized Phase Ii ◽  
Related Quality ◽  
Health Related ◽  
Grade Ii

Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial

2019 ◽  
Vol 75 (6) ◽  
pp. 940-947 ◽  
Author(s):  
Daniel J. Khalaf ◽  
Katherine Sunderland ◽  
Bernhard J. Eigl ◽  
Christian K. Kollmannsberger ◽  
Nikita Ivanov ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Randomized Trial ◽  
Phase Ii ◽  
Health Related Quality ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Related Quality ◽  
Health Related

Health-Related Quality of Life in Patients Treated With Temozolomide Versus Procarbazine for Recurrent Glioblastoma Multiforme

2000 ◽  
Vol 18 (7) ◽  
pp. 1481-1491 ◽  
Author(s):  
D. Osoba ◽  
M. Brada ◽  
W.K. A. Yung ◽  
M. Prados
Keyword(s):  
Quality Of Life ◽  
Glioblastoma Multiforme ◽  
Disease Progression ◽  
Recurrent Glioblastoma ◽  
Phase Iii ◽  
Health Related Quality ◽  
Recurrent Glioblastoma Multiforme ◽  
Related Quality ◽  
Health Related

PURPOSE: To determine whether chemotherapy with temozolomide (TMZ) versus procarbazine (PCB) for recurrent glioblastoma multiforme (GBM) was associated with improvement in health-related quality of life (HRQOL). PATIENTS AND METHODS: HRQOL was assessed at baseline and during treatment using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 and a Brain Cancer Module (BCM20) in two clinical trials that enrolled a total of 366 patients. Two hundred eighty-eight patients provided HRQOL data that could be used for analysis; 109 patients received TMZ in a phase II study, whereas 89 patients received TMZ and 90 received PCB in a randomized phase III study. Changes from baseline in the scores of seven preselected HRQOL domains (role and social functioning, global quality of life [QOL], visual disorders, motor dysfunction, communication deficit, and drowsiness) were calculated for all groups. Statistical significance, effect sizes, and proportions of patients with improved HRQOL scores (changes of ≥ 10 points) were calculated. RESULTS: Before disease progression, patients treated with TMZ were found to have an improvement in most of the preselected HRQOL domain scores compared with their baseline (pretreatment) scores. Those who were progression-free on TMZ at 6 months had improvement in all the preselected HRQOL domains. Conversely, patients treated with PCB reported deterioration in HRQOL that was independent of whether or not the disease had progressed by 6 months. Patients with disease progression, regardless of treatment, experienced a sharp decline in all domains at the time of progression. CONCLUSION: Treatment with TMZ was associated with improvement in HRQOL scores compared with treatment with PCB. The deterioration reported by PCB-treated patients was likely because of toxicity. Delaying disease progression by treatment with TMZ is beneficial to the HRQOL status of patients with recurrent GBM.

Lacosamide Added to Concomitant AEDs Grouped by Mechanism of Action: Impact on Patient-Reported Health-Related Quality of Life in Pooled Phase II/III Trials (P06.114)

Neurology ◽  
2012 ◽  
Vol 78 (Meeting Abstracts 1) ◽  
pp. P06.114-P06.114
Author(s):  
M. De Backer ◽  
S. Borghs ◽  
D. Herbert ◽  
J.-K. Sake ◽  
J. Cramer
Keyword(s):  
Quality Of Life ◽  
Phase Ii ◽  
Mechanism Of Action ◽  
Health Related Quality ◽  
Patient Reported ◽  
Related Quality ◽  
Health Related ◽  
Reported Health

scholarly journals Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC

2019 ◽  
Vol 14 (5) ◽  
pp. 793-801 ◽  
Author(s):  
Fabrice Barlesi ◽  
Edward B. Garon ◽  
Dong-Wan Kim ◽  
Enriqueta Felip ◽  
Ji-Youn Han ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Phase Ii ◽  
Health Related Quality ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Related Quality ◽  
Health Related ◽  
Previously Treated
Sign in / Sign up

Export Citation Format

Share Document